ライフサイエンスコーパス: duloxetine

1 o may respond optimally to therapies such as duloxetine.

2 d randomized trial comparing placebo pill to duloxetine.

3 a moderate recommendation for treatment with duloxetine.

4 e followed by placebo or placebo followed by duloxetine.

5 nanomolar range and is comparable to that of duloxetine.

6 significantly increased starting at 120 mg/d duloxetine.

7 icantly at 2 weeks of treatment with 80 mg/d duloxetine (11.3 at baseline, 3.4 at 240 mg/d, P<0.001).

8 n treatments (CBT: 10.2, escitalopram: 11.1, duloxetine: 11.2).

9 treatment with escitalopram (10-20 mg/day), duloxetine (30-60 mg/day), or CBT (16 50-minute sessions

10 treatments (CBT: 41.9%, escitalopram: 46.7%, duloxetine: 54.7%).

11 , subjects were randomly assigned to receive duloxetine 60 mg twice a day (n = 104) or placebo (n = 1

12 lind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the sh

13 was rapidly normalized by spinal delivery of duloxetine acting via 5-hydroxytryptamine type 2A recept

14 enrolled patients, 127 patients treated with duloxetine and 128 who received placebo were evaluable f

15 Duloxetine and comparator SSRI.

16 orepinephrine/serotonin reuptake inhibitors (duloxetine and milnacipran) in fibromyalgia.

17 onin and norepinephrine-reuptake inhibitors--duloxetine and milnacipran--and the anticonvulsant prega

18 adrenaline re-uptake inhibitors, for example duloxetine and milnacipran.

19 difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).

20 Duloxetine and SSRI did not differ in efficacy, and comp

21 settings, the analgesic actions of the SNRI duloxetine and the SSRI fluoxetine were differentially a

22 IRs were similar among duloxetine and untreated patients (0.5/1000 PY [95 % CI:

23 mm Hg (PD30) increased dose-dependently with duloxetine and was significant at the end of the 120-mg/

24 drugs as first-line therapy, or tramadol or duloxetine as second-line therapy.

25 Individuals receiving duloxetine as their initial 5-week treatment reported a

26 veral other pharmaceutical agents, including duloxetine, atomoxetine, fluoxetine and tolterodine.

27 done, phenelzine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine, and agomel

28 clinical trial, we found that treatment with duloxetine, but not placebo, normalized DMN connectivity

29 modafinil, levodopa, rotigotine, clozapine, duloxetine, clonazepam, ramelteon, gabapentin, zonisamid

30 arge, randomized placebo-controlled trial of duloxetine collected before and 8 weeks after treatment.

31 py-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in

32 Duloxetine compared with placebo improved (pooled risk d

33 0.82 points lower for patients who received duloxetine compared with those who received placebo (95%

34 uncovered in 6/19 participants a tendency of duloxetine enhancing predicted placebo response, while i

35 depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milna

36 line, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtaz

37 Duloxetine exerts only modest relief of male stress urin

38 ignificantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and ven

39 , patients were randomized to receive either duloxetine followed by placebo or placebo followed by du

40 Conclusion Results of treatment with duloxetine for AIMSS were superior to those of placebo a

41 stress urinary incontinence, confirming that duloxetine had a modest positive effect in men with post

42 Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse even

43 pion hydrochloride, citalopram hydrobromide, duloxetine hydrochloride, escitalopram oxalate, fluoxeti

44 Effects of duloxetine hydrochloride, selective serotonin reuptake i

45 Duloxetine improved but did not resolve urinary incontin

46 study further examines the hepatic safety of duloxetine in a large US health insurance database.

47 antidepressant medications (escitalopram and duloxetine) in patients with major depression and examin

48 gher but not statistically significant among duloxetine initiators compared to initiators of venlafax

49 hepatic-related death or liver failure among duloxetine initiators compared to venlafaxine and possib

50 Among 30,844 duloxetine initiators, 21,000 were matched to venlafaxin

51 is ineffective for acute low back pain, and duloxetine is associated with modest effects for chronic

52 Duloxetine is US Food and Drug Administration approved f

53 ived treatment with escitalopram (n = 22) or duloxetine (n = 14) for 10 weeks.

54 cebo and active-comparator phase 3 trials of duloxetine (n = 2515).

55 cally antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophe

56 naline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7.7 (6.5-9.4) for prega

57 olerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0.31, 95% CrI 0.13 to 0.95)

58 ine were significantly more efficacious than duloxetine (odds ratios [OR] 1.39, 1.33, 1.30 and 1.27,

59 first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks.

60 Patients were randomly assigned 1:1 to duloxetine or placebo for 13 weeks.

61 of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules

62 as by randomizing patients to receive either duloxetine or placebo, and it supported true causal infe

63 For example, high-dose duloxetine outperformed escitalopram in treating core em

64 ised after 2 weeks of treatment with 80 mg/d duloxetine (P<0.001), the lowest dose used in the study.

65 away linearly modeled placebo analgesia from duloxetine response, we uncovered in 6/19 participants a

66 Gabapentin and duloxetine reversed mechanical hyperalgesia but did not

67 e and alprazolam (RR = 1.86); loratadine and duloxetine (RR = 1.94); loratadine and ropinirole (RR =

68 lafaxine (SMD, -1.53 [CrI, -2.41 to -0.65]), duloxetine (SMD, -1.33 [CrI, -1.82 to -0.86]), and amitr

69 Duloxetine, strontium ranelate, and NGF antibodies are p

70 sion and without liver disease who initiated duloxetine to comparators (venlafaxine or selective sero

71 in another 6/19, we uncovered a tendency for duloxetine to diminish it.

72 nd in the wastewater effluent ranged from 3 (duloxetine) to 2190 ng/L (venlafaxine), whereas individu

73 th placebo-treated female subjects (n = 92), duloxetine-treated female subjects (n = 92) demonstrated

74 verse events of any grade were higher in the duloxetine-treated group (78% v 50%); rates of grade 3 a

75 improvement on most efficacy measures, while duloxetine-treated male subjects (n = 12) failed to impr

76 Plasma from duloxetine-treated subjects (ex vivo effect) dose-depend

77 Compared with placebo-treated subjects, duloxetine-treated subjects had significantly greater re

78 Compared with placebo-treated subjects, duloxetine-treated subjects improved significantly more

79 Duloxetine treatment improved fibromyalgia symptoms and

80 Hepatic injury has been reported following duloxetine use.

81 ty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo r

82 Duloxetine was administered in a randomized, placebo-con

83 trial (with a 1-week placebo lead-in phase), duloxetine was an effective and safe treatment for many

84 Duloxetine was approved for the treatment of chronic kne

85 onic low back pain than previously observed, duloxetine was effective for chronic low back pain, and

86 Duloxetine was not significantly different from placebo

87 Duloxetine was safely administered and well tolerated.

88 newly developed ones, such as pregabalin and duloxetine, while specifically marketed for diabetic neu

89 The primary hypothesis was that duloxetine would be more effective than placebo in decre

90 We hypothesized that treatment of AIMSS with duloxetine would improve average joint pain compared wit